The Future of Cancer Treatment: Cutting-Edge Advances in Immuno-Oncology
November 8, 2024
Imagine a future where cancer treatment is as precise and personalized as it is powerful, where the body’s own defenses are guided to hunt down and destroy tumors. This vision is becoming reality through immuno-oncology (IO), a transformative field empowering the immune system to selectively attack cancer cells. Unlike traditional treatments like chemotherapy and radiation, […]
GSK’s $300M Acquisition of Chimagen’s CMG1A46: A Deep Dive into B Cell-Targeted Trispecific T Cell Engagers
November 4, 2024
On October 29, GSK made headlines with a $300 million upfront payment to acquire Chimagen Biosciences’ clinical-stage asset, CMG1A46, a dual-target CD19/CD20 trispecific T cell engager (TCE). This acquisition signals GSK’s commitment to advancing therapies for B-cell-driven autoimmune diseases, such as systemic lupus erythematosus and lupus nephritis, with possible applications in other autoimmune conditions. B […]
